<h1>PF-06252616 is an experimental compound designed to block the myostatin protein, a natural limiter of muscle growth.
MDA has long supported myostatin inhibition as a potential strategy for the treatment of Duchenne muscular dystrophy and other muscular dystrophies.</h1>
BY MARGARET WAHL...
boys
compound
dmd
dosage
drug
dystrophy
experimental
function
group
growth
inhibition
muscle
muscular
myostatin
participants
period
pf-06252616
pf-0625616
pfizer
phase
placebo
receive
sites
study
trial
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.